Big congratulations to our portfolio company Resistell for recruiting first patients to their multicenter clinical study in Switzerland (Lausanne), Spain (Madrid) and Austria (Innsbruck) with the aim to assess the sensitivity, specificity, accuracy and time to result of the Resistell Phenotech device in testing the antibiotic susceptibility of Gram-negative bacteria, including E. coli and K. pneumoniae, to clinically relevant antibiotics.
Resistell_Press_Release_February_2023
About HEMEX
HEMEX is committed to changing the future of healthcare by guiding the most promising European startups through each and every step to bring innovative pharmaceuticals, medical devices, and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure startups have access to a wide range of tailored products, practical solutions, and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit https://hemex.ch/